New expertise to scale a lab-in-the-loop future Scaling this vision takes more than technology, it requires deep expertise in oncology, translational biology, and pharma strategy. Two exceptional ...

Dimerix, Audeara, LTR Pharma and EZZ Life Science are among ASX health companies reporting quarterly results this week. ... Read More The post ASX Health Quarterly Wrap: Dimerix inks fourth licensing ...

Discover why diverse patient voices, especially first-time participants, are key to improving clinical trials. Boost ...

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional ...

In recently reported case studies, nemolizumab, approved for two indications associated with itch, has been reported to be ...

Dozens of unsecured creditors are facing losses of $3m as the fallout from the winding down of a popular medicinal cannabis ...

The ASX was up 0.6% at lunch time in the eastern states, riding a wave of momentum from the mining giants once again.

The B.C. NDP government’s handling of a costly treatment for a rare disease in a 10-year-old girl has put the spotlight on a ...

A school district in Maryland is among among hundreds of districts and state officials seeking hundreds of millions of dollars in compensatory damages for years of dealing with the harm caused by ...

The SAB brings together internationally recognised experts in NET biology, pre-clinical development, and immunology. The founding members include Dr. Tim Hammond, Professor John Hamilton, Dr.

Salarius also announces continued progress in its planned merger with Decoy Therapeutics Inc. (Decoy). Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly ...

OncoZenge Provides Market and Strategy UpdateOncoZenge AB (publ) (“OncoZenge” or “the Company”) today announced a comprehensive market and strategy update after successfully securing full funding for ...